List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7636865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 425-434.	4.9	589
2	Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurology, The, 2009, 8, 679-690.	4.9	458
3	ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia, 2018, 38, 1026-1037.	1.8	416
4	Migraine. New England Journal of Medicine, 2020, 383, 1866-1876.	13.9	376
5	Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia, 2010, 30, 1179-1186.	1.8	365
6	PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain, 2009, 132, 16-25.	3.7	360
7	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurology, The, 2014, 13, 1100-1107.	4.9	333
8	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 382-390.	4.9	312
9	Migraine: epidemiology and systems of care. Lancet, The, 2021, 397, 1485-1495.	6.3	310
10	A Systematic Comparison of Motion Artifact Correction Techniques for Functional Near-Infrared Spectroscopy. Frontiers in Neuroscience, 2012, 6, 147.	1.4	304
11	Migraine and the trigeminovascular system—40 years and counting. Lancet Neurology, The, 2019, 18, 795-804.	4.9	294
12	Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet, The, 2019, 394, 1030-1040.	6.3	269
13	Migraine and structural changes in the brain. Neurology, 2013, 81, 1260-1268.	1.5	264
14	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. Journal of Headache and Pain, 2019, 20, 6.	2.5	260
15	Evidence for a vascular factor in migraine. Annals of Neurology, 2011, 69, 635-645.	2.8	252
16	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	1.8	245
17	Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurology, The, 2013, 12, 454-461.	4.9	244
18	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia, 2020, 40, 241-254.	1.8	230

#	Article	IF	CITATIONS
19	Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain, 2014, 137, 779-794.	3.7	196
20	Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 2021, 17, 501-514.	4.9	194
21	Human models of migraine — short-term pain for long-term gain. Nature Reviews Neurology, 2017, 13, 713-724.	4.9	165
22	Erenumab in chronic migraine with medication overuse. Neurology, 2019, 92, e2309-e2320.	1.5	163
23	Calcitonin gene-related peptide and pain: a systematic review. Journal of Headache and Pain, 2017, 18, 34.	2.5	161
24	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	1.8	154
25	Migraine. Nature Reviews Disease Primers, 2022, 8, 2.	18.1	154
26	Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, The, 2021, 397, 1496-1504.	6.3	141
27	Migraine: integrated approaches to clinical management and emerging treatments. Lancet, The, 2021, 397, 1505-1518.	6.3	139
28	Post-traumatic headache: epidemiology and pathophysiological insights. Nature Reviews Neurology, 2019, 15, 607-617.	4.9	131
29	Erenumab (AMG 334) in episodic migraine. Neurology, 2017, 89, 1237-1243.	1.5	120
30	Longâ€ŧerm efficacy and safety of erenumab in migraine prevention: Results from a 5â€year, open″abel treatment phase of a randomized clinical trial. European Journal of Neurology, 2021, 28, 1716-1725.	1.7	112
31	Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia, 2012, 32, 140-149.	1.8	111
32	Provocation of migraine with aura using natural trigger factors. Neurology, 2013, 80, 428-431.	1.5	107
33	Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks. JAMA Neurology, 2018, 75, 1187.	4.5	106
34	Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain, 2017, 140, 1633-1642.	3.7	105
35	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia, 2020, 40, 1026-1044.	1.8	105
36	Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia, 2018, 38, 1611-1621.	1.8	104

#	Article	IF	CITATIONS
37	The PACAP Receptor: A Novel Target for Migraine Treatment. Neurotherapeutics, 2010, 7, 191-196.	2.1	97
38	Migraine induced by hypoxia: an MRI spectroscopy and angiography study. Brain, 2016, 139, 723-737.	3.7	97
39	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. Journal of Headache and Pain, 2018, 19, 91.	2.5	97
40	Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain, 2019, 142, 2644-2654.	3.7	94
41	Therapeutic novelties in migraine: new drugs, new hope?. Journal of Headache and Pain, 2019, 20, 37.	2.5	91
42	Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain, 2016, 157, 2773-2781.	2.0	90
43	Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain, 2014, 137, 2951-2959.	3.7	88
44	Experimental activation of the sphenopalatine ganglion provokes cluster-like attacks in humans. Cephalalgia, 2013, 33, 831-841.	1.8	86
45	Change in brain network connectivity during PACAP38-induced migraine attacks. Neurology, 2016, 86, 180-187.	1.5	86
46	Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience. Cephalalgia, 2013, 33, 540-553.	1.8	83
47	Longâ€Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial. Headache, 2011, 51, 73-84.	1.8	82
48	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia, 2019, 39, 1455-1464.	1.8	79
49	Early onset of efficacy with erenumab in patients with episodic and chronic migraine. Journal of Headache and Pain, 2018, 19, 92.	2.5	78
50	Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. Brain, 2016, 139, 2015-2023.	3.7	74
51	Migraine and magnetic resonance spectroscopy: a systematic review. Current Opinion in Neurology, 2017, 30, 246-262.	1.8	74
52	Meningeal contribution to migraine pain: a magnetic resonance angiography study. Brain, 2019, 142, 93-102.	3.7	74
53	Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia, 2020, 40, 543-553.	1.8	74
54	Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia, 2010, 30, 1443-1457.	1.8	72

#	Article	IF	CITATIONS
55	Altered thalamic connectivity during spontaneous attacks of migraine without aura: A resting-state fMRI study. Cephalalgia, 2018, 38, 1237-1244.	1.8	71
56	Calcitonin gene–related peptide does not cause the familial hemiplegic migraine phenotype. Neurology, 2008, 71, 841-847.	1.5	70
57	Current understanding of thalamic structure and function in migraine. Cephalalgia, 2019, 39, 1675-1682.	1.8	70
58	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia, 2019, 39, 1475-1487.	1.8	69
59	Prostaglandin E ₂ induces immediate migraine-like attack in migraine patients without aura. Cephalalgia, 2012, 32, 822-833.	1.8	68
60	Sphenopalatine ganglion neuromodulation in migraine: What is the rationale?. Cephalalgia, 2014, 34, 382-391.	1.8	68
61	Serotonergic mechanisms in the migraine brain – a systematic review. Cephalalgia, 2017, 37, 251-264.	1.8	68
62	Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns. Cephalalgia, 2020, 40, 554-564.	1.8	67
63	Migraine and structural abnormalities in the brain. Current Opinion in Neurology, 2014, 27, 309-314.	1.8	66
64	Emerging migraine treatments and drug targets. Trends in Pharmacological Sciences, 2011, 32, 352-359.	4.0	65
65	A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia, 2021, 41, 33-44.	1.8	65
66	Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. Journal of Headache and Pain, 2019, 20, 98.	2.5	64
67	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. Journal of Neuroscience, 2015, 35, 13800-13806.	1.7	62
68	Cortical abnormalities in episodic migraine: A multi-center 3T MRI study. Cephalalgia, 2019, 39, 665-673.	1.8	60
69	Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura. Human Brain Mapping, 2017, 38, 2635-2642.	1.9	59
70	CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia, 2019, 39, 374-389.	1.8	58
71	Dual Therapy With Anti GRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?. Headache, 2020, 60, 1056-1065.	1.8	58
72	Amylin Analog Pramlintide Induces Migraineâ€ŀike Attacks in Patients. Annals of Neurology, 2021, 89, 1157-1171.	2.8	58

#	Article	IF	CITATIONS
73	Interhemispheric differences of fMRI responses to visual stimuli in patients with sideâ€fixed migraine aura. Human Brain Mapping, 2014, 35, 2714-2723.	1.9	57
74	PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia, 2020, 40, 57-67.	1.8	57
75	Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. Lancet Neurology, The, 2021, 20, 460-469.	4.9	56
76	Prostaglandins in migraine. Current Opinion in Neurology, 2013, 26, 269-275.	1.8	53
77	Migraine with visual aura associated with thicker visual cortex. Brain, 2018, 141, 776-785.	3.7	52
78	Triptans and CGRP blockade – impact on the cranial vasculature. Journal of Headache and Pain, 2017, 18, 103.	2.5	50
79	Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia, 2019, 39, 1798-1808.	1.8	50
80	Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. Journal of Headache and Pain, 2020, 21, 62.	2.5	50
81	Calcitonin Geneâ€Related Peptide Does Not Cause Migraine Attacks in Patients With Familial Hemiplegic Migraine. Headache, 2011, 51, 544-553.	1.8	49
82	What have we learnt from triggering migraine?. Current Opinion in Neurology, 2010, 23, 259-265.	1.8	48
83	Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain, 2021, 144, 2322-2332.	3.7	48
84	Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia, 2017, 37, 136-147.	1.8	46
85	Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain, 2008, 139, 106-116.	2.0	44
86	Migraine and cluster headache – the common link. Journal of Headache and Pain, 2018, 19, 89.	2.5	44
87	Calcitonin gene-related peptide and disease activity in cluster headache. Cephalalgia, 2019, 39, 575-584.	1.8	44
88	Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. Journal of Headache and Pain, 2018, 19, 105.	2.5	43
89	Sensory migraine aura is not associated with structural grey matter abnormalities. NeuroImage: Clinical, 2016, 11, 322-327.	1.4	42
90	The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine. Journal of Headache and Pain, 2017, 18, 90.	2.5	42

#	Article	IF	CITATIONS
91	Heterogenous migraine aura symptoms correlate with visual cortex functional magnetic resonance imaging responses. Annals of Neurology, 2017, 82, 925-939.	2.8	41
92	Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine. Neurotherapeutics, 2018, 15, 371-376.	2.1	40
93	Hemiplegic Migraine Aura Begins With Cerebral Hypoperfusion: Imaging in the Acute Phase. Headache, 2011, 51, 1289-1296.	1.8	38
94	A New Technology for Detecting Cerebral Blood Flow: A Comparative Study of Ultrasound Tagged NIRS and 133Xe-SPECT. Neurocritical Care, 2012, 17, 139-145.	1.2	38
95	Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches. JAMA Network Open, 2021, 4, e2118543.	2.8	38
96	Trigger factors for familial hemiplegic migraine. Cephalalgia, 2011, 31, 1274-1281.	1.8	36
97	Prevalence and risk of migraine in patients with rosacea: A population-based cohort study. Journal of the American Academy of Dermatology, 2017, 76, 454-458.	0.6	36
98	Levcromakalim, an Adenosine Triphosphate‧ensitive Potassium Channel Opener, Dilates Extracerebral but not Cerebral Arteries. Headache, 2019, 59, 1468-1480.	1.8	36
99	Prevalence of neck pain in migraine: A systematic review and meta-analysis. Cephalalgia, 2022, 42, 663-673.	1.8	36
100	Hypersensitivity to Calcitonin Gene–Related Peptide in Postâ€Traumatic Headache. Annals of Neurology, 2020, 88, 1220-1228.	2.8	35
101	Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain, 2021, 162, 2512-2520.	2.0	35
102	CGRP in Human Models of Migraine. Handbook of Experimental Pharmacology, 2018, 255, 109-120.	0.9	34
103	Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia, 2021, 41, 294-304.	1.8	34
104	The effect of sumatriptan on cephalic arteries: A 3T MR-angiography study in healthy volunteers. Cephalalgia, 2013, 33, 1009-1016.	1.8	33
105	The Role of Endothelin in the Pathophysiology of Migraine—a Systematic Review. Current Pain and Headache Reports, 2018, 22, 27.	1.3	32
106	Cranial parasympathetic activation induces autonomic symptoms but no cluster headache attacks. Cephalalgia, 2018, 38, 1418-1428.	1.8	32
107	Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. Journal of Headache and Pain, 2021, 22, 78.	2.5	32
108	Effect of CGRP and sumatriptan on the BOLD response in visual cortex. Journal of Headache and Pain, 2012, 13, 159-166.	2.5	31

#	Article	IF	CITATIONS
109	Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 125-135.	1.8	31
110	Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Doubleâ€Blind Placeboâ€Controlled Phase 3 Clinical Studies. Headache, 2019, 59, 1788-1801.	1.8	31
111	Structural gray matter abnormalities in migraine relate to headache lateralization, but not aura. Cephalalgia, 2015, 35, 3-9.	1.8	30
112	Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia, 2020, 40, 1212-1223.	1.8	30
113	Spontaneous Low-Frequency Oscillations in Cerebral Vessels: Applications in Carotid Artery Disease and Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2010, 19, 465-474.	0.7	29
114	Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. Cephalalgia, 2011, 31, 683-690.	1.8	29
115	Post-Traumatic Stress Disorder After Traumatic Brain Injury—A Systematic Review and Meta-Analysis. Neurological Sciences, 2020, 41, 2737-2746.	0.9	29
116	Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine. Neurology, 2021, 96, e2488-e2499.	1.5	29
117	Calcitonin Gene-Related Peptide Modulates Heat Nociception in the Human Brain - An fMRI Study in Healthy Volunteers. PLoS ONE, 2016, 11, e0150334.	1.1	29
118	Coexisting typical migraine in familial hemiplegic migraine. Neurology, 2010, 74, 594-600.	1.5	28
119	Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT _{1B} Receptor Binding. JAMA Neurology, 2019, 76, 834.	4.5	27
120	Calcitonin gene-related peptide and migraine with aura: A systematic review. Cephalalgia, 2014, 34, 695-707.	1.8	26
121	High brain serotonin levels in migraine between attacks: A 5-HT4 receptor binding PET study. NeuroImage: Clinical, 2018, 18, 97-102.	1.4	26
122	CGRP in human models of primary headaches. Cephalalgia, 2018, 38, 353-360.	1.8	26
123	Low 5-HT _{1B} receptor binding in the migraine brain: A PET study. Cephalalgia, 2018, 38, 519-527.	1.8	26
124	Challenges in developing drugs for primary headaches. Progress in Neurobiology, 2017, 152, 70-88.	2.8	25
125	Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia, 2017, 37, 114-124.	1.8	25
126	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia, 2021, 41, 6-16.	1.8	25

#	Article	IF	CITATIONS
127	Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. Journal of Headache and Pain, 2021, 22, 22.	2.5	25
128	Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. Journal of Headache and Pain, 2010, 11, 309-316.	2.5	24
129	Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D ₂ (PGD ₂). Cephalalgia, 2011, 31, 65-76.	1.8	24
130	Migraine and risk of hemorrhagic stroke: a study based on data from general practice. Journal of Headache and Pain, 2014, 15, 74.	2.5	24
131	PACAP38 in human models of primary headaches. Journal of Headache and Pain, 2017, 18, 110.	2.5	24
132	The relationship between migraine and rosacea: Systematic review and meta-analysis. Cephalalgia, 2018, 38, 1387-1398.	1.8	24
133	Vancouver Declaration on Global Headache Patient Advocacy 2018. Cephalalgia, 2018, 38, 1899-1909.	1.8	24
134	Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). Journal of Headache and Pain, 2019, 20, 60.	2.5	24
135	Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 680-689.	2.4	24
136	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia, 2021, 41, 279-293.	1.8	24
137	The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache. Journal of Headache and Pain, 2011, 12, 551-559.	2.5	23
138	Pro-inflammatory and vasoconstricting prostanoid PGF _{2α} causes no headache in man. Cephalalgia, 2011, 31, 1532-1541.	1.8	23
139	Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Cephalalgia, 2017, 37, 74-88.	1.8	23
140	lctal neck pain investigated in the interictal state – a search for the origin of pain. Cephalalgia, 2020, 40, 614-624.	1.8	23
141	Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. Journal of Headache and Pain, 2021, 22, 68.	2.5	23
142	Cerebral Asymmetry of fMRI-BOLD Responses to Visual Stimulation. PLoS ONE, 2015, 10, e0126477.	1.1	23
143	Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia, 2019, 39, 1407-1420.	1.8	22
144	Opening of BK _{Ca} channels alters cerebral hemodynamic and causes headache in healthy volunteers. Cephalalgia, 2020, 40, 1145-1154.	1.8	22

#	Article	IF	CITATIONS
145	Neck pain and headache after whiplash injury: a systematic review and meta-analysis. Pain, 2020, 161, 880-888.	2.0	22
146	Measurement of Blood Flow Velocity in the Middle Cerebral Artery During Spontaneous Migraine Attacks: A Systematic Review. Headache, 2017, 57, 852-861.	1.8	21
147	Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1685-1694.	2.4	21
148	Risk Factors for the Development of Postâ€Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review. Headache, 2020, 60, 1066-1075.	1.8	20
149	Hypersensitivity to calcitonin gene-related peptide in chronic migraine. Cephalalgia, 2021, 41, 701-710.	1.8	20
150	Vascular changes have a primary role in migraine. Cephalalgia, 2012, 32, 428-430.	1.8	19
151	The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. Cephalalgia, 2013, 33, 301-307.	1.8	19
152	Carbon monoxide may be an important molecule in migraine and other headaches. Cephalalgia, 2014, 34, 1169-1180.	1.8	19
153	Measurement precision and biological variation of cranial arteries using automated analysis of 3 T magnetic resonance angiography. Journal of Headache and Pain, 2014, 15, 25.	2.5	19
154	PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache, 2017, 57, 56-63.	1.8	19
155	Effect of the H ₁ -antihistamine clemastine on PACAP38 induced migraine. Cephalalgia, 2019, 39, 597-607.	1.8	19
156	Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. Cephalalgia, 2021, 41, 731-748.	1.8	19
157	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. Cephalalgia, 2021, 41, 1135-1151.	1.8	19
158	Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura. JAMA Neurology, 2022, 79, 159.	4.5	19
159	Hypoxic mechanisms in primary headaches. Cephalalgia, 2017, 37, 372-384.	1.8	18
160	Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil. Cephalalgia, 2019, 39, 1776-1788.	1.8	18
161	Extracranial activation of ATP-sensitive potassium channels induces vasodilation without nociceptive effects. Cephalalgia, 2019, 39, 1789-1797.	1.8	18
162	Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study. Peptides, 2019, 121, 170134.	1.2	18

#	Article	IF	CITATIONS
163	Latest Insights into the Pathophysiology of Migraine: the ATP-Sensitive Potassium Channels. Current Pain and Headache Reports, 2020, 24, 77.	1.3	18
164	The Stereotypical Image of a Person With Migraine According to Mass Media. Headache, 2020, 60, 1465-1471.	1.8	18
165	Targeting BKCa Channels in Migraine: Rationale and Perspectives. CNS Drugs, 2020, 34, 325-335.	2.7	18
166	Increased neck muscle stiffness in migraine patients with ictal neck pain: A shear wave elastography study. Cephalalgia, 2020, 40, 565-574.	1.8	18
167	Clutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 604-616.	2.4	18
168	Low frequency oscillations in cephalic vessels assessed by near infrared spectroscopy. European Journal of Clinical Investigation, 2012, 42, 1180-1188.	1.7	17
169	PACAP38 dose-response pilot study in migraine patients. Cephalalgia, 2017, 37, 391-395.	1.8	17
170	Feasibility of Glutamate and GABA Detection in Pons and Thalamus at 3T and 7T by Proton Magnetic Resonance Spectroscopy. Frontiers in Neuroscience, 2020, 14, 559314.	1.4	17
171	Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. Journal of Headache and Pain, 2020, 21, 134.	2.5	17
172	Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia, 2020, 40, 1276-1282.	1.8	17
173	Effect of K _{ATP} channel blocker glibenclamide on levcromakalim-induced headache. Cephalalgia, 2020, 40, 1045-1054.	1.8	17
174	Brain barriers and their potential role in migraine pathophysiology. Journal of Headache and Pain, 2022, 23, 16.	2.5	17
175	Pharmacological modulation of the bOLD response: A study of acetazolamide and glyceryl trinitrate in humans. Journal of Magnetic Resonance Imaging, 2011, 34, 921-927.	1.9	16
176	Intravenous Endothelinâ€1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura. Headache, 2020, 60, 724-734.	1.8	16
177	Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta. Cephalalgia, 2014, 34, 712-716.	1.8	15
178	Structural asymmetry of cortical visual areas is related to ocular dominance. NeuroReport, 2015, 26, 1071-1076.	0.6	15
179	Effect of motion artifacts and their correction on near-infrared spectroscopy oscillation data: a study in healthy subjects and stroke patients. Journal of Biomedical Optics, 2015, 20, 056011.	1.4	15
180	Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol. Cephalalgia, 2018, 38, 892-903.	1.8	15

#	Article	IF	CITATIONS
181	Toward a pragmatic migraine model for drug testing: 1. Cilostazol in healthy volunteers. Cephalalgia, 2016, 36, 172-178.	1.8	14
182	Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0ÂT. Journal of Headache and Pain, 2018, 19, 44.	2.5	14
183	The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. Cephalalgia, 2020, 40, 1474-1488.	1.8	14
184	Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1328-1337.	2.4	14
185	Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers. Cephalalgia, 2021, 41, 99-111.	1.8	14
186	Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. Pharmacology Research and Perspectives, 2021, 9, e00741.	1.1	14
187	The Effect of KATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers. Frontiers in Physiology, 2021, 12, 652136.	1.3	14
188	The chronobiology of migraine: a systematic review. Journal of Headache and Pain, 2021, 22, 76.	2.5	14
189	Mechanistic Investigations Support Liver Safety of Ubrogepant. Toxicological Sciences, 2020, 177, 84-93.	1.4	13
190	Migraine and light: A narrative review. Headache, 2022, 62, 4-10.	1.8	13
191	Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers. Journal of Headache and Pain, 2009, 10, 85-91.	2.5	12
192	The L-kynurenine signalling pathway in trigeminal pain processing: A potential therapeutic target in migraine?. Cephalalgia, 2011, 31, 1029-1038.	1.8	12
193	Post procedure headache in patients treated for neurovascular arteriovenous malformations and aneurysms using endovascular therapy. Journal of Headache and Pain, 2016, 17, 73.	2.5	12
194	Migraine is associated with high brain 5-HT levels as indexed by 5-HT ₄ receptor binding. Cephalalgia, 2019, 39, 526-532.	1.8	12
195	Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. Journal of Headache and Pain, 2020, 21, 19.	2.5	12
196	Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura. Headache, 2020, 60, 655-664.	1.8	12
197	Intradural artery dilation during experimentally induced migraine attacks. Pain, 2021, 162, 176-183.	2.0	12
198	PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Management, 2021, 11, 647-654.	0.7	12

#	Article	IF	CITATIONS
199	Low-frequency oscillations and vasoreactivity of cortical vessels in obstructive sleep apnea during wakefulness: A near infrared spectroscopy study. Sleep Medicine, 2013, 14, 416-421.	0.8	11
200	Altered Low Frequency Oscillations of Cortical Vessels in Patients with Cerebrovascular Occlusive Disease – A NIRS Study. Frontiers in Neurology, 2013, 4, 204.	1.1	11
201	Can nitric oxide induce migraine in normal individuals?. Cephalalgia, 2015, 35, 1125-1129.	1.8	11
202	Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. Peptides, 2015, 74, 33-42.	1.2	11
203	Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. Journal of Headache and Pain, 2018, 19, 11.	2.5	11
204	Sildenafil and calcitonin gene-related peptide dilate intradural arteries: A 3T MR angiography study in healthy volunteers. Cephalalgia, 2019, 39, 264-273.	1.8	11
205	Infusion of Pituitary Adenylate Cyclase–Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. Journal of Investigative Dermatology, 2021, 141, 1687-1698.	0.3	11
206	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. Journal of Headache and Pain, 2021, 22, 81.	2.5	11
207	Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study. Journal of Headache and Pain, 2021, 22, 98.	2.5	11
208	Prevalence of right-to-left shunts on transcranial Doppler in chronic migraine and medication-overuse headache. Cephalalgia, 2014, 34, 37-41.	1.8	10
209	Association of acetazolamide infusion with headache and cranial artery dilation in healthy volunteers. Pain, 2014, 155, 1649-1658.	2.0	10
210	Migraine with aura in women is not associated with structural thalamic abnormalities. NeuroImage: Clinical, 2020, 28, 102361.	1.4	10
211	The migraine landscape on YouTube: A review of YouTube as a source of information on migraine. Cephalalgia, 2020, 40, 1363-1369.	1.8	10
212	Natriuretic peptides and cerebral hemodynamics. Regulatory Peptides, 2014, 192-193, 15-23.	1.9	9
213	A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.63-e1.	0.9	9
214	Carbon monoxide inhalation induces headache in a human headache model. Cephalalgia, 2018, 38, 697-706.	1.8	9
215	Sphenopalatine ganglion stimulation induces changes in cardiac autonomic regulation in cluster headache. Clinical Physiology and Functional Imaging, 2018, 38, 808-815.	0.5	9
216	The most important advances in headache research in 2018. Lancet Neurology, The, 2019, 18, 5-6.	4.9	9

#	Article	IF	CITATIONS
217	Timing and durability of response to erenumab in patients with chronic migraine. Headache, 2021, 61, 1255-1263.	1.8	9
218	Updates in the Diagnostic Approach of Headache. Current Pain and Headache Reports, 2021, 25, 80.	1.3	9
219	Coogling migraine: A study of Google as an information resource of migraine management. Cephalalgia, 2020, 40, 1633-1644.	1.8	8
220	Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. Expert Opinion on Drug Safety, 2021, 20, 867-876.	1.0	8
221	Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity. Headache, 2021, 61, 1180-1193.	1.8	8
222	Human Cerebral Perfusion, Oxygen Consumption, and Lactate Production in Response to Hypoxic Exposure. Cerebral Cortex, 2022, 32, 1295-1306.	1.6	8
223	PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia, 2022, 42, 687-695.	1.8	8
224	Evidence of a Christmas spirit network in the brain: functional MRI study. BMJ, The, 2015, 351, h6266.	3.0	7
225	Volume of the rectus capitis posterior minor muscle in migraine patients: a cross-sectional structural MRI study. Journal of Headache and Pain, 2020, 21, 57.	2.5	7
226	Interictal pontine metabolism in migraine without aura patients: A 3 Tesla proton magnetic resonance spectroscopy study. NeuroImage: Clinical, 2021, 32, 102824.	1.4	7
227	Facial pain and multiple cranial palsies in a patient with skin cancer. Journal of Headache and Pain, 2011, 12, 381-383.	2.5	6
228	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan. Scandinavian Journal of Pain, 2013, 4, 211-216.	0.5	6
229	Migraine without aura is not associated with incomplete circle of Willis: a case–control study using high-resolution magnetic resonance angiography. Journal of Headache and Pain, 2014, 15, 27.	2.5	6
230	Endovascular thrombectomy and post-procedural headache. Journal of Headache and Pain, 2017, 18, 10.	2.5	6
231	High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. Peptides, 2019, 112, 43-47.	1.2	6
232	Vancouver Declaration II on Global Headache Patient Advocacy 2019. Cephalalgia, 2020, 40, 1017-1025.	1.8	6
233	Nitric Oxide Modulation of Lowâ \in Frequency Oscillations in Cortical Vessels in FHM â \in " a NIRS Study. Headache, 2012, 52, 1146-1154.	1.8	5
234	Ultrasound tagged near infrared spectroscopy does not detect hyperventilation-induced reduction in cerebral blood flow. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 82-87.	0.6	5

#	Article	IF	CITATIONS
235	Carbon monoxide inhalation induces headache but no migraine in patients with migraine without aura. Cephalalgia, 2018, 38, 1940-1949.	1.8	5
236	Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?. Journal of Headache and Pain, 2018, 19, 33.	2.5	5
237	Ultra-high field MR angiography in human migraine models: a 3.0 T/7.0 T comparison study. Journal of Headache and Pain, 2019, 20, 48.	2.5	5
238	Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). BMJ Open, 2020, 10, e039445.	0.8	5
239	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia, 2019, 39, 1058-1066.	1.8	4
240	S100B and NSE in Cluster Headache – Evidence for Glial Cell Activation?. Headache, 2020, 60, 1569-1580.	1.8	4
241	Post-traumatic stress disorder attributed to traumatic brain injury in children – a systematic review. Brain Injury, 2020, 34, 857-863.	0.6	4
242	Subtype-Specific Off-Label Treatment of Rosacea. Case Reports in Dermatology, 2021, 13, 121-128.	0.3	4
243	Longâ€ŧerm efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. Headache, 2022, 62, 624-633.	1.8	4
244	CGRP in migraine. Journal of Headache and Pain, 2009, 10, 385-385.	2.5	3
245	Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients. Cephalalgia, 2020, 40, 966-977.	1.8	3
246	Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. Cephalalgia, 2021, 41, 1262-1267.	1.8	3
247	Calcitonin gene-related peptide — beyond migraine prophylaxis. Nature Reviews Neurology, 2019, 15, 562-564.	4.9	2
248	Reducing Episodic Cluster Headaches: Focus on Galcanezumab. Journal of Pain Research, 2020, Volume 13, 1591-1599.	0.8	2
249	Intravascular Endothelin-1 does not trigger or increase susceptibility to Spreading Depolarizations. Journal of Headache and Pain, 2020, 21, 127.	2.5	2
250	Reply: Hyperpolarization through ATP-sensitive potassium channels; relevance to migraine pathology. Brain, 2020, 143, e14-e14.	3.7	2
251	l Reunión Post-European Headache Federation: revisión de las novedades presentadas en el Congreso de la European Headache Federation de 2020. Revista De Neurologia, 2021, 72, S1.	7.6	2
252	Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine. Headache, 2021, 61, 916-926.	1.8	2

#	Article	IF	CITATIONS
253	Intracranial and extracranial arteries in migraine – Authors' reply. Lancet Neurology, The, 2013, 12, 848-849.	4.9	1
254	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	1.7	1
255	The temporal evolution of a facial pain syndrome associated with neurovascular contact: a case report. Journal of Headache and Pain, 2015, 16, 12.	2.5	1
256	The changing faces of migraine. Journal of Headache and Pain, 2019, 20, 52.	2.5	1
257	Neurovascular origin of primary headaches. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 571-572.	2.4	1
258	Extracranial source of increased CGRP in migraine children?. Cephalalgia, 2010, 30, 380-381.	1.8	0
259	How Specific Is the Translational Animal Model of Trigeminal Autonomic Cephalalgias?. Headache, 2015, 55, 204-205.	1.8	0
260	Lifelong contribution to headache science: A tribute to Professor Jes Olesen. Cephalalgia, 2017, 37, 7-7.	1.8	0
261	Board Walk – October 2019. Cephalalgia, 2019, 39, 1470-1471.	1.8	0
262	Board Walk – August 2021. Cephalalgia, 2021, 41, 1033-1034.	1.8	0
263	Neuropeptides and channels: Data from clinical trials and experimental models. Journal of the Neurological Sciences, 2021, 429, 117918.	0.3	0
264	Greater Occipital Nerve Block with Local Anesthetics and Corticosteroids in Treatment-Resistant Chronic Migraine. Headache Medicine, 0, , 160-167.	0.1	0